Fig. 2.

Heterologous prime/boost vaccination elicits dramatic expansion of tumor-specific CD8⁺ T cells and slows tumor progression. a % OVA-specific CD8⁺ T cells was assessed in the blood on d15 following MIS416 Vax () or MIS416 Vax + MRB-OVA () (n = 15). b Compiled survival data of d5 tumor-bearing mice following MIS416 Vax () or MIS416 Vax + MRB-OVA () (n = 15–17). c Tumor progression in mice following MIS416 Vax alone () or in combination with MRB-CONT (♦) or MRB-OVA () (n = 4–5). d Tumor progression in mice following MIS416 Vax + MRB-OVA alone (NT, ●) or in combination with CD8α depletion (anti-CD8α,) (n = 4–5). Data presented as mean ± SEM. Data in c and d are from one representative experiment